Imaging-guided Parenchymal Liver Biopsy: How We Do It.

J Clin Imaging Sci

Department of Radiology, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01655, USA.

Published: November 2011

Liver biopsies are performed for both focal and nonfocal lesions (parenchymal). In our center, majority of liver biopsies are performed for parenchymal liver disease. Parenchymal liver biopsy plays a key role in the diagnosis of various diffuse liver dysfunctions. Results of the biopsy help grade the disease, facilitating prognostication, which helps in planning specific treatment strategies. Imaging guidance is gaining wide acceptance as the standard procedure. Ultrasound (US) guidance is currently considered the most cost-effective and safe way to perform parenchymal liver biopsies. Radiologists worldwide and particularly in the United States are increasingly performing this procedure. Radiologists performing biopsies generally use the cutting needle. Different needle sizes, techniques and preference for biopsy of the right or left lobe have been described. We attribute these preferences to prior training and individual radiologist's comfort level. We describe the algorithm followed at our institution for performing percutaneous US-guided parenchymal liver biopsy. While clinical societies have recommended a minimum of 40 liver biopsies as a requirement for proficiency of clinicians, specific to radiology trainees/fellows interested in pursuing a career in intervention, we feel a total of 20 liver biopsies (includes assisted and independently performed biopsies under supervision) should be adequate training.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3177433PMC
http://dx.doi.org/10.4103/2156-7514.82082DOI Listing

Publication Analysis

Top Keywords

parenchymal liver
20
liver biopsies
20
liver biopsy
12
liver
10
biopsies performed
8
biopsies
7
biopsy
5
parenchymal
5
imaging-guided parenchymal
4
biopsy liver
4

Similar Publications

Hepatic encephalopathy (HE) is traditionally associated with hepatic parenchymal diseases, such as acute liver failure and cirrhosis. Its prevalence in non-cirrhotic portal hypertension (NCPH) patients, extrahepatic portal vein obstruction (EHPVO), and non-cirrhotic portal fibrosis (NCPF) is less well described. HE in NCPH allows one to study the effect of portosystemic shunting and ammonia without significant hepatic parenchymal injury.

View Article and Find Full Text PDF

Mesenchymal stromal cells-extracellular vesicles: protein corona as a camouflage mechanism?

Extracell Vesicles Circ Nucl Acids

November 2024

Laboratorio di Biotecnologie Applicate all'Ortopedia, IRCCS Ospedale Galeazzi - Sant'Ambrogio, Milano 20157, Italy.

Mesenchymal stromal cells (MSCs) showed promising potential for regenerative and therapeutic applications for several pathologies and conditions. Their potential is mainly ascribed to the factors and extracellular vesicles (EVs) they release, which are now envisioned as cell-free therapeutics in cutting-edge clinical studies. A main cornerstone is the preferential uptake by target cells and tissues, in contrast to clearance by phagocytic cells or removal from circulation before reaching the final destination.

View Article and Find Full Text PDF

Malnutrition is a common health problem affecting overall body functions, growth, and development. The aim of the present study was to explore any potential changes in solid organ sizes due to malnutrition and, if so, their correlation with the degree of malnutrition. Solid organ sizes (liver, spleen, and kidneys) in patients with primary malnutrition were measured prospectively using ultrasonography.

View Article and Find Full Text PDF

Most gene therapies exert their actions via manipulation of hepatocytes (parenchymal cells) and the reasons behind the suboptimal performance of synthetic mRNA in non-parenchymal cells (NPC) such as Kupffer cells (KC), and liver macrophages, remain unclear. Here, the spatio-temporal distribution of mRNA encoding enhanced green fluorescent protein (Egfp), siRNA, or both co-encapsulated into lipid nanoparticles (LNP) in the liver in vivo using real-time intravital imaging is investigated. Although both KC and hepatocytes demonstrate comparable high and rapid uptake of mRNA-LNP and siRNA-LNP in vivo, the translation of Egfp mRNA occurs exclusively in hepatocytes during intravital imaging.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!